Henry Schein, Inc.
HSICHealthcareNASDAQMedical Distribution
Scan Results
Daily timeframeHenry Schein, Inc. provides health care products and services to office-based dental and medical practitioners worldwide. Valued at $10.01B, HSIC is a large-cap name in its sector. It operates through Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology segments.
Market Cap
$10.01B
Beta
0.81
P/E (TTM)
26.18
P/E (Fwd)
14.97
EPS (TTM)
$3.43
EPS (Fwd)
$6.00
ROE
8.8%
ROA
4.4%
Cash
$157.0M
Total Debt
$3.81B
Free CF
$446.0M
52W Change
32.8%
Annual Financials
Cash vs Debt
Where HSIC stands vs its 150-day and 200-day moving averages
As of the August 24, 2026 close, HSIC finished 11.59% above its 150-day moving average ($79.31) and 13.19% above its 200-day moving average ($78.19). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is HSIC overbought or oversold?
At the August 24, 2026 close, HSIC's RSI(14) was 60.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, HSIC has $157.0M in cash with $3.81B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company generates $446.0M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 8.8% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 4.4% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $12.65B (2022) to $13.18B (2025).
The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing HSIC.